Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb's Videx (ddl)

Executive Summary

FDA's Antiviral Drugs Advisory Committee is expected to review the NDA for Videx at its July 18-19 meeting. The AIDS drug will be discussed on both days. The meeting is tentatively scheduled to be held at the Holiday Inn in Bethesda, Maryland. In an April 18 letter to David Barr of the Gay Men's Health Crisis, FDA CDER Director Carl Peck said the advisory committee would review ddl in "early July." Barr, on behalf of ACT UP, called for Videx to be reviewed in 30 days.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel